Ra Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Phase 2 gMG long-term extension data show durability of zilucoplan treatment effect, with sustained improvements in primary and secondary endpoints…
Pharmaceuticals, Biotechnology and Life Sciences
Phase 2 gMG long-term extension data show durability of zilucoplan treatment effect, with sustained improvements in primary and secondary endpoints…
YCGP’s “With Love, Me” Letters Campaign Brings Together Cancer Survivors and Caregivers to Share Their Heartfelt Personal Stories with Others…
–Conference Call and Webcast Today at 8:00 a.m. ET– WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused…
On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in…
Increasing visibility of potential study participants to sites and sponsors DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug…
The Focused Interferon Therapeutics (FIT) platform is a proprietary targeted antibody-interferon fusion technology with potential broad application in oncology This…
PRINCETON, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt; lt;a href="https://twitter.com/hashtag/BMS?src=hash" target="_blank"gt;#BMSlt;/agt;–Bristol-Myers Squibb Company (NYSE: BMY) today announced the Phase 3 CheckMate -498 trial…
Top European VC leads 28-7’s Series A extension with $15 million and brings financing to over $80 million PARIS–(BUSINESS WIRE)–Sofinnova…
STRASBOURG, France–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Transgene?src=hash" target="_blank"gt;#Transgenelt;/agt;–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against…
Transgene Combined General Meeting (ordinary and extraordinary sessions) ofTransgene’s shareholders will be held on May 22, 2019,